AZD7789 is AstraZeneca’s key investigational PD-1/TIM-3 bispecific monoclonal antibody, which will be the first to enter the clinic in the U.S. in 2021, with indications for advanced solid tumors and hematologic malignancies. Here, HAVCR2 is linked to hematologic disorder.